Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03259373 · ClinicalTrials.gov registry record · NA
IMplementation of an RCT to imProve Treatment With Oral AntiCoagulanTs in Patients With Atrial Fibrillation
A NA study, sponsored by Harvard Pilgrim Health Care.
- Completed
- Registry status
- NA
- Development phase
- 64,666
- Enrollment target
NCT03259373: Completed NA study, sponsored by Harvard Pilgrim Health Care.
NCT03259373 is a NA study that has completed, run by Harvard Pilgrim Health Care. The registered enrollment target is 64,666 participants, above the 1,402-participant average among 58,714 other NA trials with a reported enrollment target (4512% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03259373, a NA study, has completed, sponsored by Harvard Pilgrim Health Care.
- COMPLETED
- Registry status
- NA
- Development phase
- 64,666 participants
- Enrollment target
Study Summary
The purpose of this study is to use a decentralized claims database to determine whether education on stroke prevention in atrial fibrillation (AF) among AF patients and their providers can result in increased use of oral anticoagulants (OAC) for stroke prevention among those AF patients with guideline-based indications for oral anticoagulation (CHA₂DS₂-VASc score of 2 or greater). Specifically, the investigators will conduct a prospective, randomized, open-label education intervention trial to evaluate the effect of the early patient and provider education interventions on the proportion of patients with evidence of at least one OAC prescription fill (defined as one OAC dispensing or 4 international normalized ratio \[INR tests\] over the course of the follow-up through the date on which at least 80% of eligible study participants have at least 12 months of follow-up time). A total of approximately 80,000 patients will be enrolled within multiple major health plans across the United States. The randomization will be performed by the central coordinating center, and the health plans will mail the educational intervention materials to their members and providers.
Primary Outcome
Evaluate the effect of the patient and provider education interventions (versus usual care with delayed provider education intervention) on the proportion of patients with evidence of at least one OAC prescription fill (defined as one OAC dispensing or 4 INR tests) over the course of the 12 months of follow-up.
Interventions
- BEHAVIORAL Early Patient-Level and Provider-Level Educational Intervention
- BEHAVIORAL Delayed Provider-Level Educational Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64,666 participants |
| Start Date | 2017-09-25 |
| Est. Completion | 2021-12-31 |
| Phase | NA |
What the finished NCT03259373 record still lists
NCT03259373 is an interventional study that assigns participants to a tested intervention. Its 64,666 participants enrollment target places it among the larger protocols in the corpus, above the 1,402-participant average among 58,714 other NA trials with a reported enrollment target (4512% higher).
The record links to 0 conditions, and to 2 interventions - of which Early Patient-Level and Provider-Level Educational Intervention is the first listed.
NCT03259373 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03259373 about?
NCT03259373 is a clinical study titled "IMplementation of an RCT to imProve Treatment With Oral AntiCoagulanTs in Patients With Atrial Fibrillation". The purpose of this study is to use a decentralized claims database to determine whether education on stroke prevention in atrial fibrillation (AF) among AF patients and their providers can result in increased use of oral anticoagulants (OAC) for stroke prevention among those AF patients with guidel...
What is the current status of trial NCT03259373?
This trial is currently completed. It is a NA study. The enrollment target is 64,666 participants. The study started on 2017-09-25. Estimated completion is 2021-12-31.
What interventions are being tested in trial NCT03259373?
The interventions under investigation include: Early Patient-Level and Provider-Level Educational Intervention (BEHAVIORAL), Delayed Provider-Level Educational Intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT03259373?
This trial is sponsored by Harvard Pilgrim Health Care, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03259373's enrollment target sits among peer trials
64,666 4th of 2000 higher than 1,997 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04473833 · 65,000 participants · NA
Transvaginal Ultrasonography as a Screening Method for Ovarian Cancer
- NCT05128006 · 63,200 participants
Direct-to-patient Teledermatology and Computer-assisted Diagnosis
- NCT06003192 · 63,000 participants · NA
Screen Smart: Using Digital Health to Improve HIV Screening and Prevention
- NCT05723614 · 61,770 participants · NA
TRUsted rEsidents and Housing Assistance to Decrease Violence Exposure in New Haven
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI